The use of topical tacrolimus is indicated for atopic dermatitis resistant to cosrticosteroids (9,10). Tacrolimus (a calcineurin inhibitor) inhibits transduction signaling pathways in T cells after binding to a specific cytoplasmic immunophiline (FKBP12), in the presence of calcium, thus inhibiting transcription and synthesis of IL-2, IL-2, IL-2 5 and other cytokines such as GM-CSF, TNF-α and IFN (10). This evidence concerns the gene FKBP1A and atopic eczema.